These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9352383)

  • 1. Bioavailability of Desmin, a low molecular weight dermatan sulfate, after subcutaneous administration to healthy volunteers.
    Miglioli M; Pironi L; Ruggeri E; Serra C; Zamboni V; Barbanti M; Canova N; Calanni F; Milani MR; Palazzini E
    Int J Clin Lab Res; 1997; 27(3):195-8. PubMed ID: 9352383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers.
    Harenberg J; Jeschek M; Acker M; Malsch R; Huhle G; Heene DL
    Blood Coagul Fibrinolysis; 1996 Jan; 7(1):49-56. PubMed ID: 8845462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of desmin (low molecular weight dermatan sulphate) in healthy volunteers following intravenous bolus administration of different dosages (200, 400, 800 mg).
    Dettori AG; Milani MR; Manotti C; Zamboni V; Palazzini E; Barbanti M
    Thromb Res; 1995 Aug; 79(3):249-60. PubMed ID: 8533121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic characteristics of low-molecular-weight dermatan sulphate after subcutaneous administration in acute myocardial infarction.
    Traini AM; Cervi V; Melandri G; Palazzini E; Zamboni V; Semprini F; Candiotti N; Branzi A
    J Int Med Res; 1994; 22(6):323-31. PubMed ID: 7895895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic study of low molecular weight dermatan sulphate (Desmin) after a single subcutaneous administration in patients with renal insufficiency.
    Saivin S; Boneu B; Ducret F; Pourrat J; Palazzini E; Zamboni W; Duchêne P; Houin G
    Arzneimittelforschung; 2000 Sep; 50(9):821-6. PubMed ID: 11050699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of LMW dermatan sulphate: long-term persistence of intact material.
    Dawes J
    Thromb Haemost; 1993 Apr; 69(4):339-43. PubMed ID: 8497846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers.
    Tripodi A; Moia M; Bottasso B; Tenconi PM; Gianese F; Mannucci PM
    Thromb Res; 1991 Jun; 62(6):663-72. PubMed ID: 1926059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers.
    Fossler MJ; Barrett JS; Hainer JW; Riddle JG; Ostergaard P; van der Elst E; Sprogel P
    Am J Health Syst Pharm; 2001 Sep; 58(17):1614-21. PubMed ID: 11556655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute and chronic effects of a new low molecular weight dermatan sulphate (Desmin 370) on blood coagulation and fibrinolysis in healthy subjects.
    Legnani C; Palareti G; Biagi R; Ludovici S; Maggiore L; Milani MR; Coccheri S
    Eur J Clin Pharmacol; 1994; 47(3):247-52. PubMed ID: 7867677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a supersulfated low molecular weight heparin (IK-SSH) on different hemostatic parameters.
    Glusa E; Barthel W; Schenk J; Radziwon P; Butti A; Markwardt F; Breddin KH
    Haemostasis; 1998; 28(1):45-56. PubMed ID: 9885370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence of subcutaneous and intravenous body-weight-independent high-dose low-molecular-weight heparin Certoparin on anti-Xa, Heptest, and tissue factor pathway inhibitor activity in volunteers.
    Hoffmann U; Harenberg J; Bauer K; Huhle G; Tolle AR; Feuring M; Christ M
    Blood Coagul Fibrinolysis; 2002 Jun; 13(4):289-96. PubMed ID: 12032393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological actions of sulodexide.
    Ofosu FA
    Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low molecular weight heparin is responsible for the anti-Xa activity of Desmin 370.
    Brieger D; Dawes J
    Thromb Haemost; 1996 Feb; 75(2):286-91. PubMed ID: 8815578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin.
    Harenberg J; Malsch R; Angelescu M; Lange C; Michaelis HC; Wolf H; Heene DL
    Blood Coagul Fibrinolysis; 1996 Jun; 7(4):477-83. PubMed ID: 8840001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of a new low molecular weight dermatan sulphate (Desmin) in healthy volunteers: repeated daily intramuscular administration of 400 mg for a week.
    Dettori AG; Zamboni V; Manotti C; Canova N; Barbanti M; Palazzini E
    Thromb Res; 1996 Jul; 83(1):103-9. PubMed ID: 8837309
    [No Abstract]   [Full Text] [Related]  

  • 16. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Hirsh J; Bauer KA; Donati MB; Gould M; Samama MM; Weitz JI
    Chest; 2008 Jun; 133(6 Suppl):141S-159S. PubMed ID: 18574264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives.
    Dol F; Petitou M; Choay J; Sie P; Houin G; Boneu B
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):851-7. PubMed ID: 2483702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers.
    Harenberg J; Giese C; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1989 Jun; 61(3):357-62. PubMed ID: 2552604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic activity of Desmin 370. Comparison with a high molecular weight dermatan sulfate.
    Barbanti M; Calanni F; Babbini M; Bergonzini G; Parma B; Marchi E; Wassermann A
    Thromb Res; 1993 Sep; 71(5):417-22. PubMed ID: 8236168
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits.
    Ishida M; Nakada Y; Horiuchi M; Sakamoto F
    Arzneimittelforschung; 1998 Aug; 48(8):818-21. PubMed ID: 9748709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.